Study questions Super Citrimax appetite reducing effect, supports Glykon Technologies patent finding
October 5, 2005
Las Vegas, NV, October 5, 2005 — Dutch researchers in September 2005 (1) reported that InterHealth Nutraceutical’s Super Citrimax potassium-calcium hydroxycitric acid (HCA) salt performed poorly compared with two other HCA samples, both of which were forms of potassium hydroxycitrate. The scientists concluded that the potassium hydroxycitrates “showed to be potent inhibitors of food intake in rats, whereas Super Citrimax HCA-600-SXS showed only small and more inconsistent effects. The striking differences in efficacy between these 3 preparations indicate that low dosages of a relatively low-effective HCA preparation may have contributed to the lack of efficacy as found in several human studies.” They suggested that the poor showing by Super Citrimax may be the result of limited assimilation due to the presence of calcium and also inactive and undesirable HCA lactone. One of the researchers previously had indicated that differences in the quality of HCA salts on the market are responsible for inconsistent research findings. (2)
Glykon Technologies Group, LLC published similar research as far back as 2002. In United States Patent 6,476,071 (Clouatre , et al. November 5, 2002, “Correcting Polymorphic Metabolic Dysfunction with (–)-Hydroxycitric Acid”), the company reported that rats on a high fat diet received no weight control benefits from potassium-calcium HCA, whereas potassium hydroxycitrate strongly reduced weight gain. Several potassium HCA salts were tested by Glykon. It was found that the more fully and properly reacted the potassium salt, the greater the benefits. William Matheny, a partner at Glykon, affirms that the company produces only fully reacted HCA salts. “We are committed to efficacy. Our HCA products not only are fully reacted, but also make use of special patented delivery systems to avoid interaction with food and other ingredients.”
Glykon Technologies Group discovered and holds the rights to make claims regarding the impact of HCA on the regulation of insulin and blood sugar (Syndrome X), modulation of leptin and glucocorticoids, improvements in bone mineralization, the regulation of immune function, and control of inflammation. The company also has patented multiple technologies greatly expanding the range of available delivery forms for HCA as well as improving its assimilation and activity. Based in Las Vegas, Nevada, Glykon specializes in research, intellectual property development and licensing. On February 4, 2005, Glykon terminated its licensing agreement with Renaissance Herbs, Inc. covering uses and delivery systems for (–)-hydroxycitric acid and related products.
(1) Louter-van de Haar J, et al. Comparison of the effects of three different (-)-hydroxycitric acid preparations on food intake in rats. Nutr Metab (Lond). 2005 Sep 13;2(1):23. (2) Wielinga PY, et al. Hydroxycitric acid delays intestinal glucose absorption in rats. Am J Physiol Gastrointest Liver Physiol. 2005 Jun;288(6):G1144-9